Vivanova - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 696,690 | 1,321,857 | 2,019,311 | 4,706,538 | 4,390,964 | 3,047,107 | 2,672,925 | 3,219,734 |
| Profit before tax | - | - | 145,157 | 91,616 | 23,768 | -79,663 | -22,752 | 2,462 |
| Net profit | -47,943 | 54,607 | 121,966 | 78,781 | 6,056 | -79,663 | -22,752 | 1,533 |
| Equity | -53,057 | 1,550 | 123,516 | 124,183 | 116,398 | 36,736 | 13,984 | 15,517 |
| Liabilities | 202,642 | 192,020 | 517,888 | 884,488 | 734,469 | 701,147 | 1,196,536 | 1,194,243 |
| Non-current assets | 0 | 4,218 | 7,889 | 14,886 | 50,707 | 8,794 | 103,928 | 137,914 |
| Current assets | 149,585 | 189,352 | 633,515 | 1,011,746 | 800,160 | 674,153 | 1,106,592 | 1,071,846 |
| Total assets | 149,585 | 193,570 | 641,404 | 1,026,632 | 850,867 | 682,947 | 1,210,520 | 1,209,760 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | - | 26,976 | 21,021 |
| Social insurance contributions | - | - | - | - | - | 30,028 | 27,077 | 34,036 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +430.3% | +89.7% | +52.8% | +133.1% | -6.7% | -30.6% | -12.3% | +20.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -32.1% | 28.2% | 19.0% | 7.7% | 0.7% | -11.7% | -1.9% | 0.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 3523.0% | 98.7% | 63.4% | 5.2% | -216.9% | -162.7% | 9.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -6.9% | 4.1% | 6.0% | 1.7% | 0.1% | -2.6% | -0.9% | 0.0% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | 7.2% | 1.9% | 0.5% | -2.6% | -0.9% | 0.1% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 123.9 | 4.2 | 7.1 | 6.3 | 19.1 | 85.6 | 77.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 119,433 | 264,371 | 390,832 | 664,456 | 592,037 | 507,851 | 616,834 | 715,496 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Vivanova - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-01-22 | 2026-01-27 | 230.08 |
| 2026-01-16 | 2026-01-21 | 228.94 |
| 2026-01-01 | 2026-01-01 | 242.91 |
| 2025-12-16 | 2025-12-30 | 242.91 |
| 2025-07-25 | 2025-08-18 | 3.35 |
| 2025-07-24 | 2025-07-24 | 3.06 |
| 2025-06-17 | 2025-06-18 | 2639.75 |
| 2025-06-11 | 2025-06-16 | 0.93 |
| 2025-06-08 | 2025-06-09 | 0.93 |
| 2025-05-16 | 2025-06-04 | 0.93 |
| 2025-05-04 | 2025-05-13 | 0.44 |
| 2025-04-24 | 2025-04-29 | 0.44 |
| 2025-04-16 | 2025-04-16 | 2887.70 |
| 2025-02-18 | 2025-03-03 | 184.00 |
| 2025-01-22 | 2025-02-16 | 1.58 |
| 2024-10-24 | 2024-10-30 | 137.44 |
| 2024-10-16 | 2024-10-23 | 124.09 |
| 2024-09-17 | 2024-09-25 | 184.41 |
| 2024-07-24 | 2024-08-01 | 2255.74 |
| 2024-07-16 | 2024-07-23 | 2254.32 |
| 2024-05-16 | 2024-05-16 | 2442.72 |
| 2024-02-19 | 2024-02-25 | 58.23 |
| 2024-01-23 | 2024-02-08 | 58.26 |
| 2024-01-16 | 2024-01-22 | 48.45 |
| 2024-01-08 | 2024-01-11 | 17.09 |
| 2023-12-18 | 2024-01-07 | 19.80 |
| 2023-11-16 | 2023-12-12 | 20.05 |
| 2023-10-17 | 2023-10-29 | 2333.92 |
| 2023-02-17 | 2023-02-20 | 3843.60 |
| 2022-07-18 | 2022-07-26 | 0.23 |
| 2022-05-17 | 2022-06-12 | 0.06 |
| 2022-04-28 | 2022-05-09 | 1.04 |
| 2022-01-18 | 2022-01-18 | 2419.90 |
Vivanova - VMI tax arrears
As of 2026-09-14, the amount of overdue STI tax debt of the company Vivanova is: 1 €
| From | To | Overdue, € |
|---|---|---|
| 2026-09-01 | 2026-09-14 | 1.0 |
| 2026-08-31 | 2026-08-31 | 20.82 |
| 2026-08-28 | 2026-08-30 | 36720.82 |
| 2026-03-29 | 2026-04-02 | 0.1 |
| 2026-03-02 | 2026-03-08 | 56.11 |
| 2026-02-27 | 2026-03-01 | 56.07 |
| 2026-02-21 | 2026-02-26 | 56.0 |
| 2025-11-28 | 2025-11-28 | 28185.43 |
| 2025-09-30 | 2025-11-27 | 0.43 |
| 2025-09-28 | 2025-09-29 | 16137.5 |
| 2025-08-29 | 2025-09-19 | 3.5 |
| 2025-08-28 | 2025-08-28 | 16164.46 |
| 2025-08-27 | 2025-08-27 | 8.46 |
| 2025-08-21 | 2025-08-26 | 537.03 |
| 2025-08-15 | 2025-08-20 | 2340.07 |
| 2025-07-28 | 2025-07-28 | 21205.0 |
| 2025-06-28 | 2025-06-28 | 16846.37 |
| 2025-05-13 | 2025-05-13 | 2319.98 |
| 2025-04-28 | 2025-04-28 | 0.01 |
| 2025-04-10 | 2025-04-14 | 334.44 |
| 2025-03-15 | 2025-03-20 | 0.04 |
| 2025-03-09 | 2025-03-14 | 0.12 |
| 2025-03-02 | 2025-03-04 | 152.87 |
| 2025-02-26 | 2025-03-01 | 152.78 |
| 2025-02-20 | 2025-02-25 | 139.34 |
| 2025-02-18 | 2025-02-19 | 91.34 |
| 2025-02-14 | 2025-02-17 | 2212.34 |
| 2025-02-02 | 2025-02-13 | 0.08 |
| 2025-01-30 | 2025-01-31 | 87.52 |
| 2024-10-16 | 2024-10-16 | 411.39 |
| 2024-10-12 | 2024-10-15 | 4147.63 |
| 2024-10-02 | 2024-10-11 | 3736.24 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
MedLinija, UAB (code 303029921) is a Private Limited Liability Company engaged in wholesale of pharmaceutical and medical goods. In 2025, revenue increased to €3.22M from €2.67M in 2024, after €3.05M in 2023, showing a recovery and 20.5% year-on-year growth. The company moved from losses in 2023 (-€79.7K) and 2024 (-€22.8K) to a small net profit of €1.5K in 2025, with a near break-even margin of 0.1%. The balance sheet remained highly leveraged: total assets were €1.21M, liabilities €1.19M, and equity €15.5K at the end of 2025. Short-term assets accounted for most of the asset base at €1.07M, while long-term assets were €137.9K. Asset turnover was 2.66x, indicating relatively strong sales generation from the asset base. Revenue per employee reached €804.9K, while profit per employee was €383, reflecting efficient turnover but still very limited bottom-line profitability. Return on equity was 9.9%, supported by a very small equity base.